Asthma

Big data from social media may help anticipate emergency department visits for chronic conditions.

Tweets about asthma could provide clues to asthma-related emergency room visits.

HDM SLIT with ICS could reduce the risk of moderate or severe asthma exacerbations.

Children living in extreme poverty with conditions such as asthma or ADHD more likely to have other chronic conditions.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator combining a long-acting muscarcinic antagonist and a long-acting beta-2 agonist.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator.

Lack of social support among the leading risk factors for anxiety among COPD patients.

The results of a recent study indicate that patients with asthma cannot reduce their risk of developing the common cold by taking vitamin D supplements.

Statins may reduce morbidity and/or mortality in COPD patients.

Offering to review a patient's medication list with him or her present can help a community pharmacist connect personally with patients.

A patient presents with asthma, nasal congestion, and nasal polyps, and she says she has weird reactions to aspirin or other nonsteroidal anti-inflammatory drugs. Do you know what condition this patient may have?

HO-1 offers an attractive therapeutic target for the treatment of inflammatory conditions.

People from poor or middle-income households with conditions such as diabetes or asthma face greater risk for serious mental illness.

Magnesium sulfate for rapid administration

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses some important patient-related factors to consider when selecting among available inhalers.

Cardio selective beta blockers reduced the relative risk of COPD exacerbations in a recent study.

Cinqair is used with other medications for the maintenance treatment of severe asthma in patients aged 18 years or older.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, demonstrates proper technique for inhaler devices.

Patients with severe asthma now have a new treatment option: reslizumab (Cinqair).

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses adverse effects associated with asthma and COPD treatments.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what pharmacists should know about CAT and mMRC scores.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses how to classify symptom severity, assess control, and monitor therapy for asthma and chronic obstructive pulmonary disorder.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses the current guidelines pharmacists should refer to when selecting respiratory medication inhalers and managing asthma and chronic obstructive pulmonary disorder.

Greater than 10% of referrals to respiratory specialists are for chronic cough, given the condition's persistent, refractory nature.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what comorbid conditions to look out for among asthma and COPD patients.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what therapeutic options are available for managing asthma and chronic obstructive pulmonary disorder.

Patients who leave the hospital without their prescriptions in hand following an asthma-related visit are substantially more likely to be readmitted.

The role of pharmacists in the treatment of acute coronary syndrome, COPD, atrial fibrillation, heart failure, opioid-induced constipation, and type 2 diabetes.

Pulmicort Respules had annual sales of $217 million in the United States for 2015.

Teva Pharmaceutical Industries Ltd has launched a new strength, 1 mg/2 mL, of the generic version of budesonide inhalation suspension.